The FDA has withdrawn its approval of TG Therapeutics’ flagship lymphoma drug, Ukoniq (umbralisib), citing the possibility of increased risk of death in those taking the drug — and the company has voluntarily withdrawn the drug from market.
Source: Drug Industry Daily